Q1 2025 Oncology Institute Inc Earnings Call Transcript
Key Points
- Revenues for Q1 2025 increased by 10% compared to the prior year, driven by strong performance in the retail pharmacy and Dispensary business.
- The Dispensary segment grew over 20% in Q1 2025, contributing significantly to revenue and gross profit.
- New capitated contract wins added over 80,000 lives in the first quarter, with anticipated new contracts projected to add approximately $50 million in annualized revenue.
- Gross profit increased by 44.1% year-over-year, attributed to improved revenue and margins in both capitation and fee-for-service segments.
- The company successfully executed a partial paydown of convertible preferred debt and completed a capital raise, strengthening its financial position.
- Adjusted EBITDA loss was $5.1 million, although it was within the upper end of guidance.
- The outsourcing of clinical trials to Helios will result in deconsolidating clinical research revenue, modestly impacting full-year revenue.
- SG&A, including depreciation and amortization, was $27.2 million, representing a significant portion of revenue.
- Net loss for the quarter was $19.6 million, although it showed a slight improvement compared to the previous year.
- Free cash flow remained negative at $3.9 million, despite improvements from the previous year.
Good afternoon, and welcome to The Oncology Institute's first-quarter 2025 earnings conference call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A. At this time, I'd like to turn the conference over to Mark Hueppelsheuser, General Counsel at TOI. Thank you. You may begin.
The press release announcing The Oncology Institute's results for the first quarter of 2025 are available at the Investors section of the company's website, theoncologyinstitute.com. A replay of this call will also be available at the company's website after the conclusion of this call. Before we get started, I would like to remind you of the company's safe harbor language included within the company's press release for the first quarter 2025. Management may make forward-looking statements, including guidance and underlying assumptions. Forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
